A single-specialty memory clinic initiated lecanemab treatment in 234 patients over 14 months. The frequency of significant adverse events, including ARIA, was manageable. These results may inform discussions about the risks of anti-amyloid treatments.
No takes yet. Share an insight, caveat, or question.
Paczynski et al. (2025) studied this question.